Skip Navigation

Journal of Intellectual Property Law & Practice 2008 3(4):209-210; doi:10.1093/jiplp/jpn029
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2008). Published by Oxford University Press. All rights reserved

Current Intelligence

Current Intelligence

The first 10% of the full text of this article appears below.


   Current intelligence – by subject
 
Patents
 Advanced therapies and the outer limits of DNA regulation: new horizons for patents or a scaffold too far? (EC Regulation 1394/2007 on advanced therapy medicinal products and amending EC Directive 2001/83 and EC Regulation 726/2004)210

Federal Circuit affirms Nilssen's 15 patents unenforceable for inequitable conduct (Ole K. Nilssen and GEO Foundation, Ltd. v Osram Sylvania, Inc. and Osram Sylvania Products, Inc., 504 F.3d 1223, (Fed. . . . [Full Text of this Article]

Trade marks
Copyright
Personality rights and publicity rights

   Current intelligence – by jurisdiction
 
EU
Argentina
Germany
Spain
US

Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?